Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer (Q38897955)

7 September 2017

title

Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer (English)

1 reference

7 September 2017

0 references

1 reference

3

1 reference

7 September 2017

7

1 reference

7 September 2017

Henrique J Cardoso

1

0 references

Marília I Figueira

Marília I Figueira

4

0 references

Ricardo Marques

Ricardo Marques

5

0 references

Cátia V Vaz

Cátia V Vaz

2

0 references

Cláudio Maia

Cláudio J Maia

6

0 references

publication date

18 March 2015

1 reference

7 September 2017

1 reference

7 September 2017

volume

75

1 reference

7 September 2017

issue

9

1 reference

7 September 2017

page(s)

923-935

1 reference

7 September 2017

cites work

Cancer statistics, 2014

1 reference

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

21 January 2018

1 reference

Androgens and prostate cancer; pathogenesis and deprivation therapy.

21 January 2018

1 reference

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

21 January 2018

1 reference

Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer

21 January 2018

1 reference

Advances in androgen receptor targeted therapy for prostate cancer

21 January 2018

1 reference

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer

21 January 2018

1 reference

Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer

21 January 2018

1 reference

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer

21 January 2018

1 reference

Phase I trial of zoledronic acid imatinib mesylate (Gleevec) in patients with bone metastases

21 January 2018

1 reference

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer

21 January 2018

1 reference

PDGFRbeta and HIF-1alpha inhibition with imatinib and radioimmunotherapy of experimental prostate cancer

21 January 2018

1 reference

Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity

21 January 2018

1 reference

Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy.

21 January 2018

1 reference

STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.

21 January 2018

1 reference

In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.

21 January 2018

1 reference

Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases

21 January 2018

1 reference

Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice

21 January 2018

1 reference

Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors

21 January 2018

1 reference

C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis

21 January 2018

1 reference

Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth

21 January 2018

1 reference

The SCF/c-KIT system in the male: Survival strategies in fertility and cancer

21 January 2018

1 reference

Involvement of phospholipase Cgamma1 in mouse egg activation induced by a truncated form of the C-kit tyrosine kinase present in spermatozoa.

21 January 2018

1 reference

A novel c-kit transcript, potentially encoding a truncated receptor, originates within a kit gene intron in mouse spermatids.

21 January 2018

1 reference

Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer

21 January 2018

1 reference

Isolation of a human prostate carcinoma cell line (DU 145)

21 January 2018

1 reference

Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile

21 January 2018

1 reference

Regucalcin is under-expressed in human breast and prostate cancers: Effect of sex steroid hormones.

21 January 2018

1 reference

A new mathematical model for relative quantification in real-time RT-PCR

21 January 2018

1 reference

Transgenic overexpression of regucalcin leads to suppression of thapsigargin- and actinomycin D-induced apoptosis in the testis by modulation of apoptotic pathways.

21 January 2018

1 reference

Estrogenic regulation of testicular expression of stem cell factor and c-kit: implications in germ cell survival and male fertility

21 January 2018

1 reference

Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells

21 January 2018

1 reference

Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells

21 January 2018

1 reference

Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance

21 January 2018

1 reference

Targeting caspases in cancer therapeutics

21 January 2018

1 reference

Proliferative versus apoptotic functions of caspase-8 Hetero or homo: the caspase-8 dimer controls cell fate

21 January 2018

1 reference

Caspase-8 as a therapeutic target in cancer

21 January 2018

1 reference

The BCL-2 protein family: opposing activities that mediate cell death

21 January 2018

1 reference

Bax directly induces release of cytochrome c from isolated mitochondria

21 January 2018

1 reference

Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization

21 January 2018

1 reference

Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade

21 January 2018

1 reference

The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton

21 January 2018

1 reference

The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer

21 January 2018

1 reference

Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules

21 January 2018

1 reference

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?

21 January 2018

1 reference

Regulation of Bcl-2 proteins and of the permeability of the outer mitochondrial membrane.

21 January 2018

1 reference

A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity

21 January 2018

1 reference

Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target

21 January 2018

1 reference

Gonadotropin-releasing hormone agonists sensitize, and resensitize, prostate cancer cells to docetaxel in a p53-dependent manner

21 January 2018

1 reference

The growth inhibitory effect of p21 adenovirus on androgen-dependent and -independent human prostate cancer cells

21 January 2018

1 reference

p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2.

21 January 2018

1 reference

p21(Cip1) confers resistance to imatinib in human chronic myeloid leukemia cells

21 January 2018

1 reference

Resistance to docetaxel‐induced apoptosis in prostate cancer cells by p38/p53/p21 signaling

21 January 2018

1 reference

PI3 Kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells

21 January 2018

1 reference

VEGF inhibitors and prostate cancer therapy

21 January 2018

1 reference

Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension

21 January 2018

1 reference

Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate

21 January 2018

1 reference

Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells

21 January 2018

1 reference

Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression

21 January 2018

1 reference

Differential sensitization of different prostate cancer cells to apoptosis.

21 January 2018

1 reference

PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor

21 January 2018

1 reference

Androgen receptor is a tumor suppressor and proliferator in prostate cancer

21 January 2018

1 reference

Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer

21 January 2018

1 reference

c-kit expression profile and regulatory factors during spermatogonial stem cell differentiation

21 January 2018

1 reference

Tr-kit-induced resumption of the cell cycle in mouse eggs requires activation of a Src-like kinase

21 January 2018

1 reference

Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells

21 January 2018

1 reference

Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells

21 January 2018

1 reference

Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PROS.22976

1 reference

7 September 2017

1 reference